159 related articles for article (PubMed ID: 23342080)
1. Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study.
Lyng MB; Lænkholm AV; Tan Q; Vach W; Gravgaard KH; Knoop A; Ditzel HJ
PLoS One; 2013; 8(1):e54078. PubMed ID: 23342080
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting.
Sieuwerts AM; Lyng MB; Meijer-van Gelder ME; de Weerd V; Sweep FC; Foekens JA; Span PN; Martens JW; Ditzel HJ
Mol Oncol; 2014 Dec; 8(8):1679-89. PubMed ID: 25081647
[TBL] [Abstract][Full Text] [Related]
3. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
4. Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study.
Lyng MB; Lænkholm AV; Søkilde R; Gravgaard KH; Litman T; Ditzel HJ
PLoS One; 2012; 7(5):e36170. PubMed ID: 22623953
[TBL] [Abstract][Full Text] [Related]
5. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
6. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.
Prat A; Parker JS; Fan C; Cheang MCU; Miller LD; Bergh J; Chia SKL; Bernard PS; Nielsen TO; Ellis MJ; Carey LA; Perou CM
Ann Oncol; 2012 Nov; 23(11):2866-2873. PubMed ID: 22532584
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
8. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
[TBL] [Abstract][Full Text] [Related]
9. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
Habel LA; Shak S; Jacobs MK; Capra A; Alexander C; Pho M; Baker J; Walker M; Watson D; Hackett J; Blick NT; Greenberg D; Fehrenbacher L; Langholz B; Quesenberry CP
Breast Cancer Res; 2006; 8(3):R25. PubMed ID: 16737553
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy.
Larsen MS; Bjerre K; Giobbie-Hurder A; Lænkholm AV; Henriksen KL; Ejlertsen B; Lykkesfeldt AE; Rasmussen BB
Acta Oncol; 2012 Jul; 51(6):781-9. PubMed ID: 22462654
[TBL] [Abstract][Full Text] [Related]
12. Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer.
Kok M; Koornstra RH; Mook S; Hauptmann M; Fles R; Jansen MP; Berns EM; Linn SC; Van 't Veer LJ
Breast; 2012 Dec; 21(6):769-78. PubMed ID: 22738860
[TBL] [Abstract][Full Text] [Related]
13. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
14. A relative ordering-based predictor for tamoxifen-treated estrogen receptor-positive breast cancer patients: multi-laboratory cohort validation.
Zhou X; Li B; Zhang Y; Gu Y; Chen B; Shi T; Ao L; Li P; Li S; Liu C; Guo Z
Breast Cancer Res Treat; 2013 Dec; 142(3):505-14. PubMed ID: 24253811
[TBL] [Abstract][Full Text] [Related]
15. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.
Loi S; Haibe-Kains B; Desmedt C; Wirapati P; Lallemand F; Tutt AM; Gillet C; Ellis P; Ryder K; Reid JF; Daidone MG; Pierotti MA; Berns EM; Jansen MP; Foekens JA; Delorenzi M; Bontempi G; Piccart MJ; Sotiriou C
BMC Genomics; 2008 May; 9():239. PubMed ID: 18498629
[TBL] [Abstract][Full Text] [Related]
16. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.
Ahern TP; Cronin-Fenton DP; Lash TL; Sørensen HT; Ording AG; Hamilton-Dutoit SJ; Hellberg Y
Acta Oncol; 2016 Jun; 55(6):734-41. PubMed ID: 27056567
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.
Cai H; Li X; Li J; Ao L; Yan H; Tong M; Guan Q; Li M; Guo Z
Oncotarget; 2015 Dec; 6(42):44593-608. PubMed ID: 26527319
[TBL] [Abstract][Full Text] [Related]
18. Transcriptomic signature predicts the distant relapse in patients with ER+ breast cancer treated with tamoxifen for five years.
Zhou H; Lv Q; Guo Z
Mol Med Rep; 2018 Feb; 17(2):3152-3157. PubMed ID: 29257261
[TBL] [Abstract][Full Text] [Related]
19. A multimarker model to predict outcome in tamoxifen-treated breast cancer patients.
Linke SP; Bremer TM; Herold CD; Sauter G; Diamond C
Clin Cancer Res; 2006 Feb; 12(4):1175-83. PubMed ID: 16489071
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer.
Planas-Silva MD; Bruggeman RD; Grenko RT; Smith JS
Exp Mol Pathol; 2007 Feb; 82(1):85-90. PubMed ID: 17046747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
